A phase 1/2, open‐label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma-Reference-Cited by-同舟云学术

A phase 1/2, open‐label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma

Published:2022-10-31 Issue:1 Volume:41 Page:108-119
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Carlo‐Stella Carmelo¹,Zinzani Pier Luigi²^ORCID,Sureda Anna³,Araújo Luis⁴,Casasnovas Olivier⁵,Carpio Cecilia⁶,Yeh Su‐Peng⁷,Bouabdallah Krimo⁸,Cartron Guillaume⁹,Kim Won Seog¹⁰,Cordoba Raul¹¹,Koh Youngil¹²,Re Alessandro¹³,Alves Daniela¹⁴,Chamuleau Martine¹⁵,Le Gouill Steven¹⁶,López‐Guillermo Armando¹⁷,Moreira Ilídia¹⁸,van der Poel Marjolein W. M.¹⁹,Abbadessa Giovanni²⁰,Meng Robin²⁰,Ji Ran²⁰,Lépine Lucie²¹,Saleem Rao²⁰,Ribrag Vincent²²

Affiliation:

1. Department of Biomedical Sciences Humanitas University and Department of Oncology and Hematology IRCCS Humanitas Research Hospital Milano Italy

2. IRCCS Azienda Ospedaliero‐Universitaria di Bologna Istituto di Ematologia “Seràgnoli” and Dipartimento di Medicina Specialistica Diagnostica e Sperimentale Università di Bologna Bologna Italy

3. Institut Català D'Oncologia ‐ Hospital Duran i Reynals IDIBELL Universitat de Barcelona Barcelona Spain

4. Universitário de Coimbra Coimbra Portugal

5. Hématologie Clinique, CHU Dijon Bourgogne Dijon France

6. Department of Hematology Vall d'Hebron Institute of Oncology (VHIO) Hospital Universitari Vall d’Hebron Vall d’Hebron Barcelona Hospital Campus Universitat Autònoma de Barcelona Barcelona Spain

7. China Medical University Hospital Taichung Taiwan

8. Hematology and Cellular Therapy Department University Hospital of Bordeaux Bordeaux France

9. Department of Hematology Centre Hospitalier Universitaire Montpellier Montpellier France

10. Sungkyunkwan University School of Medicine Samsung Medical Center Seoul Korea

11. Fundación Jiménez Díaz University Hospital Madrid Spain

12. Department of Internal Medicine Seoul National University Hospital Seoul Korea

13. Hematology Division ASST Spedali Civili Brescia Brescia Italy

14. Hematology and Bone Marrow Transplant Department Hospital de Santa Maria Centro Hospitalar Universitário Lisboa Norte (CHULN) Lisbon Portugal

15. Department of Hematology Cancer Center Amsterdam on behalf of the LLPC (Lunenburg Lymphoma Phase I/II Consortium) Amsterdam University Medical Center VU University Amsterdam Amsterdam The Netherlands

16. Department of Hematology Institut Curie Paris France

17. Department of Hematology Hospital Clínic de Barcelona Barcelona Spain

18. Department of Onco‐Hematology Portuguese Institute of Oncology of Porto Porto Portugal

19. Department of Internal Medicine Division of Hematology GROW School for Oncology and Developmental Biology on behalf of the LLPC (Lunenburg Lymphoma Phase I/II Consortium) Maastricht University Medical Center Maastricht the Netherlands

20. Sanofi Cambridge Massachusetts USA

21. Sanofi Chilly‐Mazarin France

22. Département d’Hématologie et Département des Essais Précoces (DITEP) Institut Gustave Roussy Villejuif France

Funder

Sanofi

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.3089

Reference40 articles.

1. PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma

2. CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies?

3. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

4. Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Isatuximab Monotherapy for Desensitization in Highly Sensitized Patients Awaiting Kidney Transplant;Journal of the American Society of Nephrology;2023-12-26

2. Education and Empowering Special Forces to Eradicate Secret Defectors: Immune System-Based Treatment Approaches for Mature T- and NK-Cell Malignancies;Cancers;2023-04-28